Acridine carboxamide

Acridine carboxamide is a chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

Acridine carboxamide
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H19N3O
Molar mass293.363 g/mol g·mol−1
3D model (JSmol)

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]

See also

References

  1. Dittrich C, Dieras V, Kerbrat P, et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683.
  2. Caponigro F, Dittrich C, Sorensen JB, et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842.
  3. Twelves C, Campone M, Coudert B, et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748.
  4. Dittrich C, Coudert B, Paz-Ares L, et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.